Proteomic investigation in A549 lung cell line stably infected by HPV16E6/E7 oncogenes

Respiration

Volumn 77, Issue 4, 2009, Pages 427-439

  Ciotti, Marco ^a   Marzano, Valeria ^a,b,c   Giuliani, Laura ^b,d   Nuccetelli, Marzia ^a,b,c   D'Aguanno, Simona ^a,b,c   Azzimonti, Barbara ^e   Bernardini, Sergio ^a,b,c   Perno, Carlo Federico ^a   Urbani, Andrea ^a,f   Favalli, Cartesio ^a   Federici, Giorgio ^a,b,c,d  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY OF CHIETI   (Italy)

Author keywords

Human; Lung cancer; Mass spectrometry; Molecular networks; Oncogene; Papillomaviruses; Proteomics

Indexed keywords

GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; HEAT SHOCK PROTEIN 27; LIPOCORTIN 4; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MASS SPECTROMETRY; ONCOGENE PROTEINS, VIRAL; ONCOGENES; PROTEOMICS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 67649962723     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000176209     Document Type: Article

References (53)

1. Ferlay J, Bray F, Pisani P, Parkin D: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base. Lyon, IARC Press, 2001.
2. Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 2003; 123: 21S-49S.
3. Stancu M, King T, Maizel A: Molecular biology of lung cancer: a primer; in Weitberg AB, Klastersky J (eds): Cancer of the Lung. Totowa, Humana Press, 2002.
4. Syrjanen K, Syrjanen S: Papillomavirus Infections in Human Pathology. New York, Wiley, 2000.
5. zur Hausen H: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 2001; 93:252-253.
6. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
7. Ciotti M, Giuliani L, Ambrogi V, Ronci C, Benedetto A, Mineo TC, Syrjanen K, Favalli C: Detection and expression of human papillomavirus oncogenes in non-small cell lung cancer. Oncol Rep 2006; 16 : 183-189.
8. Giuliani L, Jaxmar T, Casadio C, Gariglio M, Manna A, D'Antonio D, Syrjanen K, Favalli C, Ciotti M: Detection of oncogenic viruses (SV40, BKV, JCV, HCMV, HPV) and p53 codon 72 polymorphism in lung carcinoma. Lung Cancer 2007; 57:273-281.
9. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
10. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248:76-79.
11. Dyson N, Howley PM, Munger K, Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-937.
12. Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM: Functions of human papil lomavirus proteins. Curr Top Microbiol Immunol 1994; 186:83-99.
13. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT: HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8: 3905-3910.
14. Barbosa MS, Schlegel R: The E6 and E7 genes of HPV-18 are sufficient for inducing two-stage in vitro transformation of human keratinocytes. Oncogene 1989; 4: 1529- 1532.
15. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarre M, de Villiers EM, Filotico R, Boukamp P, Tommasino M: The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003; 77: 2195 -2206.
16. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
17. Ciotti M, Sesti F, Paba P, Benedetto A, Patrizi L, Criscuolo A, Piccione E, Branca M, Syrjän-en K, Favalli C: Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic. Eur J Gynaecol Oncol 2004; 25:577-584.
18. Cheung CK, Mak YT, Swaminathan R: Automated trichloroacetic acid precipitation method for urine total protein. Ann Clin Biochem 1987; 24:140-144.
19. Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996; 68:850-858.
20. Gharahdaghi F, Kirchner M, Fernandez J, Mische SM: Peptide-mass profiles of polyvinylidene difluoride-bound proteins by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in the presence of nonionic detergents. Anal Biochem 1996; 233:94-99.
21. Hall RA, Dix BR, O'Carroll SJ, Braithwaite AW: p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998; 4:1068-1072.
22. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
23. Giuliani L, Favalli C, Syrjanen K, Ciotti M: Human papillomavirus infections in lung cancer. Detection of E6 and E7 transcripts and review of the literature. Anticancer Res 2007; 27: 2697-2704.
24. Yim EK, Meoyng J, Namkoong SE, Um SJ, Park JS: Genomic and proteomic expression patterns in HPV-16 E6 gene transfected stable human carcinoma cell lines. DNA Cell Biol 2004; 23:826-835.
25. Choi YP, Kang S, Hong S, Xie X, Cho NH: Proteomic analysis of progressive factors in uterine cervical cancer. Proteomics 2005; 5: 1481-1493.
26. Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES: Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer. Clin Chem 2007; 53: 1433-1439.
27. Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Benedetto A, Paba P, Costa S, Bonifacio D, Di Bonito P, Accardi L, Favalli C, Syrjanen K: Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 2006; 59: 40-47.
28. Kieser A, Weich HA, Brandner G, Marme D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-969.
29. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS: Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000; 19: 4611-4620.
30. 2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005; 6:449- 461.
31. Sohma H, Ohkawa H, Hashimoto E, Sakai R, Saito T: Ethanol-induced augmentation of annexin IV expression in rat C6 glioma and human A549 adenocarcinoma cells. Alcohol Clin Exp Res 2002; 26:44S-48S.
32. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC: Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 2000; 83: 83-88.
33. Park JE, Lee DH, Lee JA, Park SG, Kim NS, Park BC, Cho S: Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun 2005; 337: 1283-1287.
34. Nicchitta CV, Carrick DM, Baker-Lepain JC: The messenger and the message: gp96 (GRP94)-peptide interactions in cellular immunity. Cell Stress Chaperones 2004; 9:325- 331.
35. Wang Q, An L, Chen Y, Yue S: Expression of endoplasmic reticulum molecular chaperon GRP94 in human lung cancer tissues and its clinical significance. Chin Med J 2002; 115: 1615-1619.
36. Urbani A, Poland J, Bernardini S, Bellincampi L, Biroccio A, Schnolzer M, Sinha P, Federici G: A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 2005; 5: 796-804.
37. Arrigo AP, Paul C, Ducasse C, Manero F, Kretz -Remy C, Virot S, Javouhey E, Mounier N, Diaz-Latoud C: Small stress proteins: novel negative modulators of apoptosis induced independently of reactive oxygen species. Prog Mol Subcell Biol 2002; 28:185-204.
38. Ciocca DR, Rozados VR, Cuello Carrion FD, Gervasoni SI, Matar P, Scharovsky OG: Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin. Cell Stress Chaperones 2003; 8:26-36.
39. Mendez F, Sandigursky M, Kureekattil R P, Kenny MK, Franklin WA, Bases R: Specific stimulation of human apurinic/apyrimidinic endonuclease by heat shock protein 70. DNA Repair 2003; 2: 259-271.
40. Nadin SB, Vargas-Roig LM, Cuello-Carrion FD, Ciocca DR: Deoxyribonucleic acid damage induced by doxorubicin in peripheral blood mononuclear cells: possible roles for the stress response and the deoxyribonucleic acid repair process. Cell Stress Chaperones 2003; 8: 361-372.
41. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006; 5: 2592-2601.
42. Ciocca DR, Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10:86-103.
43. Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF: Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol 2005; 25: 3117-3126.
44. Yang Y, Yang F, Xiong Z, Yan Y, Wang X, Nishino M, Mirkovic D, Nguyen J, Wang H, Yang XF: An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 2005; 24: 4778-4788.
45. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Geant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J, Moras D, Amson R, Telerman A: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA 2004; 101:15364-15369.
46. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Geant A, Beaucourt S, Duflaut D, Besse S, Susini L, Cavarelli J, Moras D, Amson R, Telerman A: Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA 2004; 101:15364-15369.
47. Cans C, Passer BJ, Shalak V, Nancy-Portebois V, Crible V, Amzallag N, Allanic D, Tufino R, Argentini M, Moras D, Fiucci G, Goud B, Mirande M, Amson R, Telerman A: Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci USA 2003; 100: 13892-13897.
48. Langdon JM, Vonakis BM, MacDonald SM: Identification of the interaction between the human recombinant histamine releasing factor/translationally controlled tumor protein and elongation factor-1 delta (also known as eElongation factor-1B beta). Biochim Biophys Acta 2004; 1688:232-236.
49. Sonenberg N: Translation factors as effectors of cell growth and tumorigenesis. Curr Opin Cell Biol 1993; 5: 955-960.
50. Joseph P, Lei YX, Whong WZ, Ong TM: Oncogenic potential of mouse translation elongation factor-1 delta, a novel cadmium-responsive proto-oncogene. J Biol Chem 2002; 277: 6131-6136.
51. Xiao H, Neuveut C, Benkirane M, Jeang KT: Interaction of the second coding exon of Tat with human EF-1 delta delineates a mechanism for HIV-1-mediated shut-off of host mRNA translation. Biochem Biophys Res Commun 1998; 244: 384-389.
52. Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J, Fellmann M, Butz K, Poustka A, Hoppe-Seyler F: Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcription analyses. J Mol Med 2007; 85:1253-1262.
53. Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Cremoux P, de La Rochefordière A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany E, Sastre-Garou X: Identification of a proliferation gene cluster associated with HPV e6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene 2005; 24: 7094-7104.